GetTopicDetailResponse(id=ea68e602835, topicName=管理原則, introduction=管理原則, content=null, image=null, comments=4, allHits=1275, url=https://h5.medsci.cn/topic?id=76028, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=82122, tagList=[TagDto(tagId=82122, tagName=管理原則)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1756328, encodeId=d1b91e5632863, content=<a href='/topic/show?id=ea68e602835' target=_blank style='color:#2F92EE;'>#管理原則#</a>, objectTitle=免疫相關不良反應（irAE）的特點與管理原則, objectType=article, longId=180886, objectId=dea518088673, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dea518088673, replyNumber=0, likeNumber=123, createdTime=2020-02-16, rootId=0, userName=xiay994465, userId=9e7d37113131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dea518088673, moduleTitle=免疫相關不良反應（irAE）的特點與管理原則, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=dea518088673)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756327, encodeId=9e111e5632766, content=<a href='/topic/show?id=ea68e602835' target=_blank style='color:#2F92EE;'>#管理原則#</a>, objectTitle=張艷橋教授：免疫相關不良反應（irAE）的特點與管理原則, objectType=article, longId=180877, objectId=22a11808e7d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22a11808e7d5, replyNumber=0, likeNumber=93, createdTime=2019-10-16, rootId=0, userName=xiay994465, userId=9e7d37113131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22a11808e7d5, moduleTitle=張艷橋教授：免疫相關不良反應（irAE）的特點與管理原則, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=22a11808e7d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756326, encodeId=47bd1e5632610, content=<a href='/topic/show?id=ea68e602835' target=_blank style='color:#2F92EE;'>#管理原則#</a>, objectTitle=膿毒性休克的液體治療和管理原則：是時候考慮四個D概念和液體治療的四個階段, objectType=article, longId=166466, objectId=ecdf166466fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecdf166466fa, replyNumber=0, likeNumber=92, createdTime=2019-06-28, rootId=0, userName=xiay994465, userId=9e7d37113131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecdf166466fa, moduleTitle=膿毒性休克的液體治療和管理原則：是時候考慮四個D概念和液體治療的四個階段, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ecdf166466fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1756325, encodeId=e2a71e563258d, content=<a href='/topic/show?id=ea68e602835' target=_blank style='color:#2F92EE;'>#管理原則#</a>, objectTitle=專家訪談：形象化的2型糖尿病管理原則, objectType=article, longId=152006, objectId=ebbd152006cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebbd152006cd, replyNumber=0, likeNumber=92, createdTime=2019-04-04, rootId=0, userName=xiay994465, userId=9e7d37113131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebbd152006cd, moduleTitle=專家訪談：形象化的2型糖尿病管理原則, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ebbd152006cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
